share_log

6-K: Report of foreign private issuer (related to financial reporting)

6-K: Report of foreign private issuer (related to financial reporting)

6-K：外国发行人报告（业绩相关）
美股SEC公告 ·  09/26 16:37

Moomoo AI 已提取核心信息

Alterity Therapeutics, a development stage enterprise, has submitted its Corporate Governance Statement for the financial year ended June 30, 2024, as per the ASX Listing Rule 4.10.3. The statement, accurate as of September 26, 2024, outlines the company's adherence to the ASX Corporate Governance Council's Principles and Recommendations. It details the company's governance structure, including the roles and responsibilities of the Board and management, director appointments, performance reviews, and executive remuneration. The statement also addresses the company's commitment to ethical conduct, risk management, and the safeguarding of corporate reporting integrity. Alterity Therapeutics emphasizes the importance of diversity within its workforce, although it has not set specific measurable objectives for gender diversity due to the small size of its personnel. The company's Audit and Remuneration Committees are highlighted, along with their functions and the independence of their members. The statement further discusses the company's policies on communication, disclosure, shareholder rights, and remuneration, ensuring transparency and accountability in its operations.
Alterity Therapeutics, a development stage enterprise, has submitted its Corporate Governance Statement for the financial year ended June 30, 2024, as per the ASX Listing Rule 4.10.3. The statement, accurate as of September 26, 2024, outlines the company's adherence to the ASX Corporate Governance Council's Principles and Recommendations. It details the company's governance structure, including the roles and responsibilities of the Board and management, director appointments, performance reviews, and executive remuneration. The statement also addresses the company's commitment to ethical conduct, risk management, and the safeguarding of corporate reporting integrity. Alterity Therapeutics emphasizes the importance of diversity within its workforce, although it has not set specific measurable objectives for gender diversity due to the small size of its personnel. The company's Audit and Remuneration Committees are highlighted, along with their functions and the independence of their members. The statement further discusses the company's policies on communication, disclosure, shareholder rights, and remuneration, ensuring transparency and accountability in its operations.
alterity therapeutics，一家发展阶段的企业，已根据ASX上市规则4.10.3提交了截至2024年6月30日的财政年度公司治理报告。该报告截至2024年9月26日，详细列出了公司遵守ASX公司治理委员会的原则和建议。报告详细阐述了公司的治理结构，包括董事会和管理层的角色和职责、董事任命、绩效评估和高管薪酬。报告还涉及公司对道德行为、风险管理和维护公司报告诚信的承诺。alterity therapeutics强调员工多样性的重要性，尽管由于其人员规模较小，公司尚未设定具体可衡量的性别多样性目标。报告突出了公司的审计委员会和薪酬委员会，以及其成员的独立性和职能。报告进一步讨论了公司关于沟通、披露、股东权利和薪酬的政策，确保其运营中的透明度和问责制。
alterity therapeutics，一家发展阶段的企业，已根据ASX上市规则4.10.3提交了截至2024年6月30日的财政年度公司治理报告。该报告截至2024年9月26日，详细列出了公司遵守ASX公司治理委员会的原则和建议。报告详细阐述了公司的治理结构，包括董事会和管理层的角色和职责、董事任命、绩效评估和高管薪酬。报告还涉及公司对道德行为、风险管理和维护公司报告诚信的承诺。alterity therapeutics强调员工多样性的重要性，尽管由于其人员规模较小，公司尚未设定具体可衡量的性别多样性目标。报告突出了公司的审计委员会和薪酬委员会，以及其成员的独立性和职能。报告进一步讨论了公司关于沟通、披露、股东权利和薪酬的政策，确保其运营中的透明度和问责制。
有用
没用

该公告为独立文件：

独立文件1

独立文件2

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间